1Kandzari DE, Tcheng JE, Zidar JP. Coronary artery stents , evaluating new designs for contemporary percutaneous intervention[J]. Catheter Cardiovasc Interv , 2002,56 (4) : 562- 576.
2Ostrowski SR, Johansson PI. Endothelial glycocalyx degradation induces endogenous heparinization in patients with severe injury and early traumatic coagulopathy [J]. J Trauma Acute Care Surg,2012, 73(1) :60-66 .
3Roffman DS. Considerations in patients receiving oral anti platelet therapy after acute coronary syndrome and percutaneous coronary intervention [J]. Am J Health Syst Pharm,2010,67(15 Suppl 7) :S18-S24.
4Schulz S, Sibbing D. Braun S. et al. Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents [J]. Am Heart J, 201(), 160 (2): 355-361.
5Lupi A, Secco GG, Rognoni A,et al. Plasma fibrinogen levels and restenosis after primary percutaneous coronary intervention [J]. J Thromb Thrombolysis, 2012, 33 (4): 308-317.
6Bonello L, Basire A. Sabatier F, et al. Endothelial injury induced by coronary angioplasty triggers mobilization of endothelial progenitor cells in patients with stable coronary artery disease[J]. J Thromb Haemost,2006.4(5) :979-981.
7Garg R. Tellez A. Alviar C. et al. The effect of percutaneous coronary intervention on inflammatory response and endothelial progenitor cell recruitment [J]. Catheter Cardiovasc Interv, 2008.72(2): 205-209.
8Stettler C. Wandel S, Allemann Ss et al. Outcomes associated with drug-eluting and bare-metal stents , a collaborative network meta-analysis[J]. Lancet, 2007 .370(9591) :937-948.
9Wohrle] , Nusser T, Kestler H'Av et al. Comparison of the slow-release polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions[J]. Clin Res Cardiol , 2007,96(2) : 70-76.
10Stolker JM, Kennedy KF. Lindsey JB. et al. Predicting restenosis of drug-eluting stents placed in real-world clinical practice: derivation and validation of a risk model from the EVENT registry [J]. Circ Cardiovasc Interv, 2010. 3 (4): 327-334.
4Meyer ML,Jaensch A,Mons U,et al.Atrial fibrillation and longterm prognosis of patients with stable coronary heart disease:Relevance of routine electrocardiogram[J].Int J Cardiol,2015,203:1014-1015.
5Haude M,Ince H,Abizaid A,et al.Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions(BIOSOLVE-Ⅱ):6 month results of a prospective,multicentre,non-randomised,first-in-man trial[J].Lancet,2016,387(10013):31-39.
6Wihanda D,Alwi I,Yamin M,et al.Factors Associated with Instent Restenosis in Patients Following Percutaneous Coronary Intervention[J].Acta Medica Indonesiana,2015,47(3):111-113.
7Siontis GC,Stefanini GG,Mavridis D,et al.Percutaneous coronary interventional strategies for treatment of in-stent restenosis:a network meta-analysis[J].Lancet,2015,386(9994):655-664.
8Shimonaga T,Kuris u S,Watanabe N,et al.Myocardial Injury after Percutaneous Coronary Intervention for In-Stent Restenosis Versus de novo Stenosis[J].Intern Med,2015,54(18):2299-2305.
10Colombo A,Ruparelia N.Is a Drug-Eluting Stent the Default Treatment Strategy for Drug-Eluting Stent Restenosis[J].J Am Coll Cardiol,2015,66(1):34-36.
